Saturday, 31 October 2026European Markets

SIPEF, B&S Group, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - sipef (sip.br) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
sipef (sip.br) €56.40 3.61% 8.1%
b&s group (bsgr.as) €4.66 3.4% 19.86%
ldc (loup.pa) €136.00 2.59% 15.32%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sipef (sip.br)

3.61% forward dividend yield and 8.1% return on equity

sipef nv operates as an agro-industrial company. the company operates through palm, rubber, tea, and bananas and horticulture segments. it also offers crude palm oil, palm kernels, and palm kernel oil ; ribbed smoked sheets, and scraps and lumps; cut, tear, and curl tea; flowers, foliage, and bananas. the company operates in papua new guinea, ivory coast, singapore, europe, indonesia, and internationally. sipef nv was incorporated in 1919 and is headquartered in schoten, belgium.

earnings per share

as for profitability, sipef has a trailing twelve months eps of €5.71.

pe ratio

sipef has a trailing twelve months price to earnings ratio of 9.88. meaning, the purchaser of the share is investing €9.88 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.1%.

moving average

sipef's worth is higher than its 50-day moving average of €53.72 and above its 200-day moving average of €53.92.

revenue growth

year-on-year quarterly revenue growth declined by 6.4%, now sitting on 429.81m for the twelve trailing months.

volatility

sipef's last week, last month's, and last quarter's current intraday variation average was 0.73%, 0.04%, and 1.08%.

sipef's highest amplitude of average volatility was 1.20% (last week), 0.87% (last month), and 1.08% (last quarter).

volume

today's last reported volume for sipef is 3040 which is 120.77% above its average volume of 1377.

more news about sipef.

2. b&s group (bsgr.as)

3.4% forward dividend yield and 19.86% return on equity

b&s group s.a. distributes consumer goods worldwide. the company operates through six segments: liquors, beauty, personal care, food, health, and travel retail. the liquors segment distributes branded liquors to wholesalers, consumers, and e-commerce platforms. the beauty segment distributes and sells branded fragrances and cosmetics to wholesalers, consumers, and e-commerce platforms. the personal care segment distributes and sells branded personal and home care products to retailers. the food segment distributes a range of branded food and beverages products to duty-free, remote, retail, and maritime markets. the health segment distributes and sells branded medical products and equipment to maritime and remote markets, pharmacies, and travel clinics. the travel retail segment operates retail stores at international and regional airports and offers consumer electronics and multi-category assortments for consumers at travel locations. the company was founded in 1872 and is based in betzdorf, luxembourg.

earnings per share

as for profitability, b&s group has a trailing twelve months eps of €0.24.

pe ratio

b&s group has a trailing twelve months price to earnings ratio of 19.42. meaning, the purchaser of the share is investing €19.42 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.86%.

revenue growth

year-on-year quarterly revenue growth grew by 4.2%, now sitting on 2.26b for the twelve trailing months.

volume

today's last reported volume for b&s group is 14345 which is 54.47% below its average volume of 31511.

moving average

b&s group's value is under its 50-day moving average of €4.70 and higher than its 200-day moving average of €4.39.

more news about b&s group.

3. ldc (loup.pa)

2.59% forward dividend yield and 15.32% return on equity

l.d.c. s.a. produces and sells poultry and processed products in france and internationally. the company also offers ready-cooked dishes, pizzas, pancakes and biscuits, and sandwiches, as well as fresh and frozen products. it offers its products under the le gaulois, maître coq, loué, marie, poule & toque, nature & respect, drosed, goldenfood, and doux brands. the company was founded in 1909 and is based in sablé-sur-sarthe, france.

earnings per share

as for profitability, ldc has a trailing twelve months eps of €16.44.

pe ratio

ldc has a trailing twelve months price to earnings ratio of 8.27. meaning, the purchaser of the share is investing €8.27 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.32%.

volume

today's last reported volume for ldc is 292 which is 76.77% below its average volume of 1257.

volatility

ldc's last week, last month's, and last quarter's current intraday variation average was 33.39%, 5.37%, and 3.23%.

ldc's highest amplitude of average volatility was 33.39% (last week), 6.82% (last month), and 3.23% (last quarter).

more news about ldc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com